AbbVie ABBV Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $697M-61.6% | $1.82B+865% | $188M-80.0% | $941M-27.0% | $1.29B— | ||
| $444M+183% | $157M-24.9% | $209M+16.8% | $179M-56.3% | $410M+150% | ||
| $137M+136% | -$385M— | —— | -$272M-871% | -$28M+96.3% | ||
| -$87M— | —— | $156M+818% | $17M-98.9% | $1.48B+482% | ||
| $184M+636% | $25M— | $0-100% | $56M-63.9% | $155M+21.1% | ||
| -$1.59B— | —— | $1.73B— | —— | -$696M-156% | ||
| $3.83B-26.6% | $5.22B-25.7% | $7.02B+36.3% | $5.15B+215% | $1.64B-76.8% | ||
| $265M-19.5% | $329M-13.6% | $381M+41.6% | $269M+14.5% | $235M-19.2% | ||
| $0— | —— | —— | —— | $204M— | ||
| -$574M+60.8% | -$1.46B+55.2% | -$3.26B-176% | -$1.18B-60.7% | -$735M+60.8% | ||
| $3.09B+6.0% | $2.91B0.0% | $2.91B0.0% | $2.91B-0.5% | $2.93B+6.3% | ||
| $1.49B+49,533% | $3M-25.0% | $4M-66.7% | $12M-98.8% | $961M+168% | ||
| $7.99B— | —— | —— | —— | $3.99B+99.7% | ||
| $919M+122% | -$4.17B+9.2% | -$4.59B-69.4% | -$2.71B-115% | -$1.26B+81.7% | ||
| -$12M-209% | $11M— | —— | $30M+233% | $9M+120% | ||
| $4.16B+1,141% | -$400M+52.3% | -$838M-165% | $1.29B+470% | -$349M+79.9% | ||
| —— | $750.5M0.0% | $750.5M0.0% | $750.5M0.0% | $750.5M+6.8% | ||
| $150M— | —— | -$319M-1,419% | -$21M+97.1% | -$729M-537% | ||
| $22M+144% | $9M-90.0% | $90M+214% | -$79M-365% | -$17M— | ||
| $722M+6.0% | $681M-12.2% | $776M-9.7% | $859M+56.5% | $549M+1.9% | ||
| $1.75B-2.0% | $1.78B-6.1% | $1.9B0.0% | $1.9B+2.3% | $1.86B-2.0% | ||
| $2.39B+69.8% | $1.41B+81.2% | $776M-72.2% | $2.8B+84.1% | $1.52B+444% | ||
| $188M-7.4% | $203M+5.7% | $192M+3.2% | $186M+2.8% | $181M-12.1% | ||
| -$81M— | —— | -$411M+70.1% | -$1.38B-464% | $378M+121% | ||
| $150M-77.2% | $658M— | —— | —— | $628M— | ||
| $22M+144% | $9M-90.0% | $90M+214% | -$79M-365% | -$17M— | ||
| $43M+4,200% | $1M-98.7% | $77M+800% | -$11M+71.1% | -$38M+80.7% | ||
| $266M-77.1% | $1.16B-58.6% | $2.8B+198% | $940M+181% | $334M-81.4% | ||
| $2B+153% | $791M-60.6% | $2.01B— | $0— | $0— | ||
| $2M— | —— | $37M— | —— | $67M+6,600% | ||
| -$499M— | —— | —— | —— | $1.59B— | ||
| $0-100% | $8M-11.1% | $9M-99.8% | $3.75B+24.1% | $3.03B-47.5% | ||
| $2B— | —— | —— | —— | $0— | ||
| $3.56B-27.1% | $4.89B-26.4% | $6.64B+36.0% | $4.88B+249% | $1.4B-79.3% | ||
| $3.56B-27.1% | $4.89B-26.4% | $6.64B+36.0% | $4.88B+249% | $1.4B-79.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbbVie generate?
- AbbVie (ABBV) generated $21.2B in operating cash flow over the trailing twelve months.
- What is AbbVie's free cash flow?
- After $1.2B of capital expenditures, AbbVie's free cash flow was $20.0B over the trailing twelve months, up 29.9% year over year.
- Where does AbbVie's cash flow data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
